N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan
Identifieur interne : 005B25 ( Main/Exploration ); précédent : 005B24; suivant : 005B26N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan
Auteurs : J. L. Montastruc [France] ; N. Fabre [France] ; Olivier Rascol [France] ; J. M. Senard [France] ; O. Blin [France]Source :
- Movement Disorders [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Aged, Dextromethorphan (administration & dosage), Dextromethorphan (adverse effects), Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Male, Middle Aged, N-Methylaspartate (antagonists & inhibitors), N-Methylaspartate (physiology), Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Receptors, N-Methyl-D-Aspartate (drug effects), Receptors, N-Methyl-D-Aspartate (physiology).
- MESH :
- chemical , administration & dosage : Dextromethorphan, Levodopa.
- chemical , adverse effects : Dextromethorphan, Levodopa.
- chemical , antagonists & inhibitors : N-Methylaspartate.
- chemical , drug effects : Receptors, N-Methyl-D-Aspartate.
- chemical , physiology : N-Methylaspartate, Receptors, N-Methyl-D-Aspartate.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Url:
DOI: 10.1002/mds.870090226
Affiliations:
- France
- Midi-Pyrénées
- Marseille, Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 004154
- to stream Istex, to step Curation: 004154
- to stream Istex, to step Checkpoint: 003E60
- to stream PubMed, to step Corpus: 004B20
- to stream PubMed, to step Curation: 004B20
- to stream PubMed, to step Checkpoint: 004A97
- to stream Ncbi, to step Merge: 004926
- to stream Ncbi, to step Curation: 004926
- to stream Ncbi, to step Checkpoint: 004926
- to stream Main, to step Merge: 008D16
- to stream Main, to step Curation: 005B25
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name><affiliation><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2CA23A6391883DA11FD78767ECEBC77CE8F92A00</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/mds.870090226</idno><idno type="url">https://api.istex.fr/document/2CA23A6391883DA11FD78767ECEBC77CE8F92A00/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">004154</idno><idno type="wicri:Area/Istex/Curation">004154</idno><idno type="wicri:Area/Istex/Checkpoint">003E60</idno><idno type="wicri:doubleKey">0885-3185:1994:Montastruc J:n:methyl:d</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8196695</idno><idno type="wicri:Area/PubMed/Corpus">004B20</idno><idno type="wicri:Area/PubMed/Curation">004B20</idno><idno type="wicri:Area/PubMed/Checkpoint">004A97</idno><idno type="wicri:Area/Ncbi/Merge">004926</idno><idno type="wicri:Area/Ncbi/Curation">004926</idno><idno type="wicri:Area/Ncbi/Checkpoint">004926</idno><idno type="wicri:doubleKey">0885-3185:1994:Montastruc J:n:methyl:d</idno><idno type="wicri:Area/Main/Merge">008D16</idno><idno type="wicri:Area/Main/Curation">005B25</idno><idno type="wicri:Area/Main/Exploration">005B25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan</title><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology, INSERM U 317, Faculté de Médecine, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology, INSERM U 317, Faculté de Médecine, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology, INSERM U 317, Faculté de Médecine, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology, INSERM U 317, Faculté de Médecine, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical and Clinical Pharmacology, Faculté de Médecine, Marseille</wicri:regionArea><placeName><settlement type="city">Marseille</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994">1994</date><biblScope unit="vol">9</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="242">242</biblScope><biblScope unit="page" to="243">243</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2CA23A6391883DA11FD78767ECEBC77CE8F92A00</idno><idno type="DOI">10.1002/mds.870090226</idno><idno type="ArticleID">MDS870090226</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Dextromethorphan (administration & dosage)</term><term>Dextromethorphan (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>N-Methylaspartate (antagonists & inhibitors)</term><term>N-Methylaspartate (physiology)</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Receptors, N-Methyl-D-Aspartate (drug effects)</term><term>Receptors, N-Methyl-D-Aspartate (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dextromethorphan</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dextromethorphan</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>N-Methylaspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>N-Methylaspartate</term><term>Receptors, N-Methyl-D-Aspartate</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li></region><settlement><li>Marseille</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name></noRegion><name sortKey="Blin, O" sort="Blin, O" uniqKey="Blin O" first="O." last="Blin">O. Blin</name><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005B25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005B25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2CA23A6391883DA11FD78767ECEBC77CE8F92A00
|texte= N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan
}}
| This area was generated with Dilib version V0.6.23. |  |